BGI Europe A/S, A wholly-owned subsidiary of BGI Genomics Co., LTD., today announces that its HPV testing products: Human Papillomavirus (HPV) Typing Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method), and related Nucleic Acid Extraction Kit has been CE marked.
The GLOBOCAN 2018 estimates there are about 500,000 new cases of cervical cancer each year, accounting for 3.2 percent of all new cancer cases, making it the fourth most common malignancy in terms of morbidity and mortality among women. Persistent high-risk human papillomavirus (HPV) infection is the leading cause of cervical cancer and precancerous lesions.
BGI CE marked Human Papillomavirus (HPV) Typing Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) together with its applicable nucleic acid extraction kit, used for the precise typing of 17 types of high-risk and medium-risk HPV such as HPV 16, 18, 31, etc. is conducive to the early diagnosis and treatment of HPV infection as well as the prevention and control of cervical cancer.
The CE certification of the HPV test will further enhance the company’s core competitiveness in the field of tumor detection in the global market, which will have a positive impact on the company’s tumor prevention and control business.